The company, whose core competence is molecular biology, would tests in molecular virology, oncology and immunology, and infectious diseases, as well as hematology and non-hematology related assays for adult and pediatric bone marrow transplantation.
"We have planned to set up two centers in Kolkata by July this year," said Debashis Bhattacharya, president and chief executive officer.
Simbiosys will tie up with pathological laboratories and collection centers in the city and tier II towns.
The company has been engaged in contract research jobs for the past two years in the US and Europe, and in India through its wholly owned subsidiary, Simbiosys Biowares India (Pvt) Ltd.
With its primary laboratory in Bangalore, the Indian arm acts as a knowledge process outsourcing center for the parent's US and European contracts apart from serving Indian clients.
It also provides pre-clinical and clinical trial related services to pharmaceutical companies. "We will increase our exposure in clinical services now," said Bhattacharya.
Simbiosys has recently got the approval of the Federal Drugs Administration of the US for the manufacture of immuno-diagnostic assay kits and molecular diagnostic kits, and will apply for certification from the National Accreditation Board for Testing & Calibration Laboratories (NABL) and the Department of Scientific & Industrial Research (DSIR).
The company is also looking forward to getting Clinical Laboratory Improvement Amendment Certification of US.
"We will start gender determination test in US and Europe by September this year," said Swati Bhattacharyya, managing director of the company.
"Moreover, Europe would stop animal testing for non-pharmaceutical works by 2010. This would give India a lot of scope to carry out such tests apart from alternative methods for conducting tests without animals," she said.